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a median of 158/uL (range 0-1168/uL); 36/65 (55%) patients
in DGD received no G-CSF (at physician's discretion) and
those who received the drug did so starting on day 14
(median) post-transplant (range ¼11d-18d). There was no
difference in the incidence or duration of  grade III muco-
sitis, weight gain, rash or engraftment syndrome between
DGD and CGD groups. However, as shown in Table 1 the CGD
group had signiﬁcantly faster engraftment, abbreviation of
neutropenia, diminished antibiotics use, and shorter hospi-
talization. These effects were independent of CD 34 cell dose.
Primarily because of abbreviated hospital stay, there was
a 17% cost beneﬁt to the use of CGD, supporting the overall
beneﬁt of this treatment regimen for patients with MM who
receive ASCT.Table 1
Characteristics CGD group DGD group P value
Neutrophil Engraftment (days) 12 (11-14) 15 (11-20) <0.0001
Duration of neutropenia 7 (5-9) 10 (6-16) <0.0001
(ANC <500)
Duration of severe neutropenia 6 (4-9) 8 (4-10) <0.0001
(ANC < 100) days
Duration of intravenous antibiotics 5 (3-20) 8 (3-15) 0.016
Duration of hospital stay 17 (14-24) 19 (16-28) <0.0001135
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The Autologous Hematopoietic Stem Cell Transplantation
(AHSCT) is a therapeutic method used in various immuno-
logical, hematological and genetic disorders, which uses
patient's own stem cells collected from peripheral blood
after their (the stem cells) mobilization by granulocyte
colony-stimulating factors (GCS-F), in order to restore the
damaged or defective bone marrow function. Oxidative
stress and antioxidant depletion have been described during
the stages involved in AHSCT. Glutathione peroxidase is an
enzyme responsible for detoxiﬁcation of organic and inor-
ganic peroxides, which participates of enzymatic cellular
antioxidant defense. The aim of the study was to evaluate the
levels of glutathione peroxidase in various stages involving
AHSCT in patients undergoing autologous hematopoietic
stem cell transplantation. Glutathione peroxidase was
determined using the Glutathione Peroxidase Ransel kit
(Randox). We measured glutathione peroxidase levels of
eight patients at different times pre-and post-AHSCT: before
Conditioning Regimen (CR), 24 hours after chemotherapy, 10
days (D +10) and 20 days (D +20) after transplantation. There
was a statistically signiﬁcant difference in levels of gluta-
thione peroxidase after CR comparing to other times, sug-
gesting an increase in oxidative stress after chemotherapy.
According to previous studies, oxidative stress occurs acutely
after high-dose chemotherapy for AHSCT and is apparently
related to late hematological recovery. Thus, it can be sug-
gested the use of glutathione peroxidase levels, and otheroxidative stress parameters as toxicity and grafting markers
after AHSCT.136
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Introduction: Peripheral blood progenitor cell (PBPC)
mobilization with intermediate-dose cyclophosphamide (3-
4 gm/m2) (ID-CY) and G-CSF when compared to low-dose CY
(1-2 gm/m2)-based strategies, has been shown to have
a favorable risk/beneﬁt proﬁle in multiple myeloma (MM)
patients (pts) receiving novel induction therapies. However
the relative efﬁcacy of ID-CY as compared to plerixafor (P) in
PBPC mobilization in MM pts is not known. Herein we
report outcomes of ID-CY/G-CSFmobilization compared to P/
G-CSF mobilization in MM pts treated with novel
inductionregimens.
Methods: This multicenter outcomes study includes 84 pts
who underwent a planned, single autograft within 1-year
of starting induction therapy with novel chemotherapy
agents (thalidomide, lenalidomide, bortezomib). Consecu-
tive pts undergoing mobilization with ID-CY/G-CSF (3-4
gm/m2) (n¼55) at one institution were compared against
consecutive pts receiving plerixafor/G-CSF (0.24 mg/kg)
(n¼29) at a different transplant center. In order to assess
efﬁciency of PBPC mobilization, we evaluated peak
peripheral blood (PB) CD34+ cell counts, CD34+ cell yield
on day1 of collection, total CD34+ cell collection, and total
number of apheresis sessions. Mobilization failure was
deﬁned as failure to collect 2 x106 cells/kg body weight.
All pts with normal renal function received uniform
conditioning with Mel200 (MEL140 if serum creatinine
was 2 mg/dl).
Results: At baseline, the ID-CY and P cohorts were well
balanced. No difference was observed in the use of lenali-
domide (p¼0.3). Compared to P, ID-CY use was associated
with higher median peak PB CD34+ cell count (63/ml vs. 160/
ml, P¼ .01), CD34+ yield on day 1 of collection (6.5 x106/kg vs.
11.7 x106/kg, P ¼ .004), and total CD34+ cell yield (10.5 x106/
kg vs. 24.9 x106/kg, P ¼ .001). Median numbers of apheresis
sessions were 2.2 in each group (p¼0.9). No mobilization
failures were seen in either group. Therewas no difference in
the proportion of pts collecting 5x106/kg CD34+ cells in
either group (93% vs. 96%, P ¼ .6), but more pts in ID-CY
cohort collected 10x106/kg CD34+ cells (55% vs. 78%, P ¼
.02). Neutrophil engraftment was signiﬁcantly faster (9.9
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of higher infused CD34+ cell dose. Rate of adverse events
were higher in the ID-CY cohort including neutropenic fevers
(p¼0.02), intravenous antibiotic use (p¼0.03), hospitaliza-
tion (p¼0.05) and packed red cell transfusions (p¼0.007).
Conclusion: In the era of novel agents compared to P, ID-CY
produced a more robust PBPC mobilization, faster engraft-
ment, but was associated with signiﬁcantly higher (but
manageable) toxicity, and no difference in mobilization
failure rates. These data support use of either intermediate
dose - cyclophosphamide or plerixafor-based PBPC mobili-
zation in MM pts undergoing stem cell collection following
novel induction therapies.Figure 1. Log-HCMI decay curve: (A) Representative NHL patient from cluster
1; (B) Representative MM patient from cluster 2; (C) Representative NHL
patient from cluster 3.137
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Hematopoietic cell (HC) mobilization to support high dose
therapy is generally carried out using cytokines with or
without chemotherapy. The resulting HC yield and the
duration of cell collection have beenwell studied and tend to
be variable. No consistent unifying relationship has been
described which would reliably represent the kinetics of this
process between different patients. To accomplish this, the
HC yield from the mobilization procedures for 431 patients
was examined. The diagnoses were multiple myeloma
(N¼220), non-Hodgkin's lymphoma (155) and Hodgkin's
lymphoma (56). Mobilizing regimens included chemo-
therapy + GCSF (97), GCSF (232), GCSF + plerixafor (84). To
normalize the HC yield between patients, the total number of
CD34+ cells collected on a given day was divided by the
volume of blood (L) processed and was termed the HC
mobilization index (HCMI). For the combined cohort the
mean HCMI value on day 1 of apheresis (HCMI1) was 19.7
( 38.9)  106 CD34+ cells/L/day. A signiﬁcant correlation
was found between HCMI1 and the circulating CD34+ cell
count on day 1 (R2 0.69, P < 0.01), and the total HC yield in
each patient (0.97, P < 0.01). These observations were
consistent in patients with various diagnoses and receiving
different mobilizing regimens. Daily HCMI values were
plotted over days of apheresis to determine the rate of
change. A general trend of declining HCMI values over days
of apheresis was observed, with some patients showing an
initial increase. To offset the effect of the large range of HCMI
values observed, the logarithm (log) of HCMI for each day
was plotted against day of apheresis for each patient with>2
days of collection (n¼279) to give individual log-HCMI decay
curves. A quadratic equation (y¼ax2+bx+c) provided the best
ﬁt for these curves (mean R2 0.88), demonstrating a parabolic
relationship such that log HCMI increased and declined in
proportion to square of time (in days) following the start of
apheresis. It was noted that the values of coefﬁcients were
normally distributed in the study population; coefﬁcient
a (mean, -0.04  0.2), b (0.04  1.1), and c (1.7  1.2). A Two-
step cluster analysis of these coefﬁcients distinguished three
main groups (clusters) of patients. Patients in cluster 1 (38%)
tended to have an initial increase in HCMI followed by an
asymptotic decline; those in clusters 2 (50.2%) and 3 (8.6%)
displayed declines of varying magnitude. Cluster 1 showed
a higher proportion of NHL patients (p¼0.01), whereas MM
was over-represented in cluster 2 (p¼0.008), consistent withthe notion that prior chemotherapy received by NHL patients
impacted their mobilization kinetics. In conclusion, we
demonstrate that HC yield during various mobilization
procedures follows mathematically predictable kinetics
which may reﬂect underlying hematopoietic reserve.138
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Background: High-dose chemotherapy and autologous
hematopoietic stem cell transplantation (auto-HCT) is an
effective treatment for systemic light chain amyloidosis (AL).
Fluid retention and weight gain during peripheral blood
hematopoietic stem cell (PBSC) mobilization with growth
